SPINEGUARD SA (ALSGD.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALSGD - FR0011464452 - Common Stock
0.101 EUR
+0 (+2.02%)
Taking everything into account, ALSGD scores 1 out of 10 in our fundamental rating. ALSGD was compared to 62 industry peers in the Health Care Equipment & Supplies industry. ALSGD has a bad profitability rating. Also its financial health evaluation is rather negative. ALSGD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ALSGD has reported negative net income.
In the past year ALSGD has reported a negative cash flow from operations.
ALSGD had negative earnings in each of the past 5 years.
ALSGD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ALSGD (-30.66%) is worse than 79.03% of its industry peers.
ALSGD has a Return On Equity of -59.81%. This is in the lower half of the industry: ALSGD underperforms 74.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.66% | ||
| ROE | -59.81% | ||
| ROIC | N/A |
ROA(3y)-32.08%
ROA(5y)-28.89%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ALSGD (70.98%) is better than 82.26% of its industry peers.
ALSGD's Gross Margin has declined in the last couple of years.
ALSGD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.98% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
2. Health
2.1 Basic Checks
ALSGD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALSGD has more shares outstanding
The number of shares outstanding for ALSGD has been increased compared to 5 years ago.
ALSGD has a worse debt/assets ratio than last year.
2.2 Solvency
ALSGD has an Altman-Z score of -3.57. This is a bad value and indicates that ALSGD is not financially healthy and even has some risk of bankruptcy.
ALSGD has a Altman-Z score of -3.57. This is amonst the worse of the industry: ALSGD underperforms 83.87% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that ALSGD is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, ALSGD is in line with its industry, outperforming 54.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.57 |
ROIC/WACCN/A
WACC8.22%
2.3 Liquidity
A Current Ratio of 1.06 indicates that ALSGD should not have too much problems paying its short term obligations.
ALSGD has a Current ratio of 1.06. This is in the lower half of the industry: ALSGD underperforms 75.81% of its industry peers.
A Quick Ratio of 0.82 indicates that ALSGD may have some problems paying its short term obligations.
The Quick ratio of ALSGD (0.82) is worse than 66.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 42.99% over the past year.
ALSGD shows a decrease in Revenue. In the last year, the revenue decreased by -4.47%.
The Revenue has been decreasing by -7.41% on average over the past years.
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.3%
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%-13.31%
3.2 Future
Based on estimates for the next years, ALSGD will show a very strong growth in Earnings Per Share. The EPS will grow by 29.42% on average per year.
The Revenue is expected to grow by 1.70% on average over the next years.
EPS Next Y83.22%
EPS Next 2Y35.36%
EPS Next 3Y29.42%
EPS Next 5YN/A
Revenue Next Year-15.4%
Revenue Next 2Y-7.32%
Revenue Next 3Y1.7%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALSGD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSGD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALSGD's earnings are expected to grow with 29.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.36%
EPS Next 3Y29.42%
5. Dividend
5.1 Amount
No dividends for ALSGD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALSGD (12/31/2025, 7:00:00 PM)
0.101
+0 (+2.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.93M
Revenue(TTM)4.32M
Net Income(TTM)-2.56M
Analysts84.44
Price Target0.64 (533.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.85 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.06
BVpS0.05
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.66% | ||
| ROE | -59.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.98% | ||
| FCFM | N/A |
ROA(3y)-32.08%
ROA(5y)-28.89%
ROE(3y)-64.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.62%
GM growth 5Y-2.09%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 72.44% | ||
| Cap/Sales | 5.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | -3.57 |
F-Score4
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)224.93%
Cap/Depr(5y)170.12%
Cap/Sales(3y)14.42%
Cap/Sales(5y)11.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.3%
EPS Next Y83.22%
EPS Next 2Y35.36%
EPS Next 3Y29.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y1.8%
Revenue growth 5Y-7.41%
Sales Q2Q%-13.31%
Revenue Next Year-15.4%
Revenue Next 2Y-7.32%
Revenue Next 3Y1.7%
Revenue Next 5YN/A
EBIT growth 1Y42.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.56%
EBIT Next 3Y31.68%
EBIT Next 5YN/A
FCF growth 1Y65.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.24%
OCF growth 3YN/A
OCF growth 5YN/A
SPINEGUARD SA / ALSGD.PA FAQ
Can you provide the ChartMill fundamental rating for SPINEGUARD SA?
ChartMill assigns a fundamental rating of 1 / 10 to ALSGD.PA.
What is the valuation status for ALSGD stock?
ChartMill assigns a valuation rating of 1 / 10 to SPINEGUARD SA (ALSGD.PA). This can be considered as Overvalued.
Can you provide the profitability details for SPINEGUARD SA?
SPINEGUARD SA (ALSGD.PA) has a profitability rating of 1 / 10.
How financially healthy is SPINEGUARD SA?
The financial health rating of SPINEGUARD SA (ALSGD.PA) is 1 / 10.